Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 110

Sort by

Sort Order Select

Journal Articles

Feasibility and efficacy of daratumumab-vcd in transplant-ineligible elderly patients with newly diagnosed multiple myeloma: First results from the multicenter GMMG-dada study

Blood (2025) 146 (Supplement 1): 4050.

https://doi.org/10.1182/blood-2025-4050

Published: 2025

Journal Articles

Identify high-risk disease in multiple myeloma through single-cell transcriptomic detection of highly proliferative (PR) cells

Noemie Leblay, Sungwoo Ahn, Alexandra Poos, Mehmet Samur, Sheri Skerget, Holly Lee, Mansour Poorebrahim, David Jung, Sacha Benaoudia, Daniel Penaherrera, Herve Avet-Loiseau, Jonathan Keats, Nikhil Munshi, Niels Weinhold, Nizar Bahlis, Paola Neri

Blood (2025) 146 (Supplement 1): 2163.

https://doi.org/10.1182/blood-2025-2163

Published: 2025

Journal Articles

Peripheral residual disease activity assessment by MALDI-TOF mass spectrometry in patients with newly-diagnosed multiple myeloma in the GMMG-HD7 study

Blood (2025) 146 (Supplement 1): 920.

https://doi.org/10.1182/blood-2025-920

Published: 2025

Journal Articles

Phylogenetic reconstruction reveals early divergence and late expansion of focal lesions in multiple myeloma

Blood (2025) 146 (Supplement 1): 685.

https://doi.org/10.1182/blood-2025-685

Published: 2025

Journal Articles

Circulating tumor cells (CTCs) for dynamic risk assessment of patients (Pts) with smoldering multiple myeloma (SMM)

Blood (2025) 146 (Supplement 1): 493.

https://doi.org/10.1182/blood-2025-493

Published: 2025

Journal Articles

T cell fitness and tumor specificity predict immunotherapy response in multiple myeloma

Niklas Kehl, Simon Steiger, Tim Wagner, Tamara Boschert, Michael Kilian, Carsten Mueller-Tidow, Niels Weinhold, Hartmut Goldschmidt, Karsten Rippe, Marc Raab, Michael Platten, Stefan Eichmueller, Mirco Friedrich

Blood (2025) 146 (Supplement 1): 1029.

https://doi.org/10.1182/blood-2025-1029

Published: 2025

Journal Articles

Reprogrammed regulatory T cells as cytotoxic effectors drive anti-tumor immunity under bispecific T cell engager therapy

Julius Michel, Jan Frenking, Anna Metzler, Erin Meermeier, Antonia Schach, Vera Thiel, Tim Wagner, Niklas Kehl, Stefanie Huhn, Alexander Brobeil, Carsten Müller-Tidow, P. Leif Bergsagel, Hartmut Goldschmidt, Hermann Einsele, Leo Rasche, Marta Chesi, Marc Raab, Niels Weinhold, Mirco Friedrich

Blood (2025) 146 (Supplement 1): 3951.

https://doi.org/10.1182/blood-2025-3951

Published: 2025

Journal Articles

Absence of circulating tumor cells (CTCs) defines a subtype of multiple myeloma (MM) patients (Pts) with unique clinical and biological features

Blood (2025) 146 (Supplement 1): 366.

https://doi.org/10.1182/blood-2025-366

Published: 2025

Journal Articles

Applying computational modelling to a high-risk multiple myeloma data set to create novel risk stratification groupings

Orthi Shahzad, Richard Norris, Niels Weinhold, Charlotte Pawlyn, Brian Walker, Cody Ashby, Christopher Wardell, David Cairns, Martin Kaiser, Gordon Cook, Faith Davies, Mark Drayson, Roger Owen, Graham Jackson, Gareth Morgan, Simon Mitchell, John Jones

Blood (2025) 146 (Supplement 1): 5790.

https://doi.org/10.1182/blood-2025-5790

Published: 2025

Journal Articles

The evolution to hepta-refractory myeloma involves sequential loss of CD38, BCMA and GPRC5D

Blood (2025) 146 (Supplement 1): 5785.

https://doi.org/10.1182/blood-2025-5785

Published: 2025

Journal Articles

Unlocking myeloma's spatial world at the micrometer scale

Leo Rasche, Niels Weinhold

Blood (2025) 146 (15): 1744–1746.

https://doi.org/10.1182/blood.2025030205

Published: 2025

Journal Articles

Biallelic antigen escape is a mechanism of resistance to anti-CD38 antibodies in multiple myeloma

Blood (2025) 146 (13): 1575–1585.

https://doi.org/10.1182/blood.2024028107

Published: 2025

Includes: Supplemental data

Journal Articles

Mutationally Enriched Regions of the Non-Coding Genome Harbor Functionally Impactful Mutations That Dysregulate Key Genes Involved in Multiple Myeloma Pathogenesis

Blood (2024) 144 (Supplement 1): 4655.

https://doi.org/10.1182/blood-2024-211012

Published: 2024

Journal Articles

Replication Stress Induces Hyper-Apobec Mutagenesis in Multiple Myeloma

Marios Papadimitriou, Marilena Tauro, Afsaneh Panahi, Bachisio Ziccheddu, Alexandra Maria Poos, Abdessamad Youssfi Alaoui, Dario Magaletti, Mark B. Meads, Kylee H Maclachlan, Marc S. Raab, Gareth Morgan, Saad Z. Usmani, Niels Weinhold, Ola Landgren, Kenneth H. Shain, Florian Kuchenbauer, Francesco Maura

Blood (2024) 144 (Supplement 1): 3276.

https://doi.org/10.1182/blood-2024-211173

Published: 2024

Journal Articles

The CAR-Hematotox As a Risk Model to Predict Early Complications and Outcome after Bispecific T-Cell Engager Therapy in Relapsed/Refractory Multiple Myeloma

Jan H. Frenking, Christine Riedhammer, David N. Sedloev, Valentine Landrin, Mirco Julian Friedrich, Niels Weinhold, Martin K. Kortüm, Carsten Müller-Tidow, Hermann Einsele, Sandra Sauer, Leo Rasche, Marc S. Raab

Blood (2024) 144 (Supplement 1): 1952.

https://doi.org/10.1182/blood-2024-210021

Published: 2024

Journal Articles

Whole Genome Sequencing Reveals Lower Apobec-Mutational Activity in Multiple Myeloma Patients with African Ancestry Compared with Those Having European Ancestry

Kylee H Maclachlan, Marios Papadimitriou, Patrick Blaney, Tala Shekarkhand, Timothy R. Chu, Alexandra Maria Poos, Elizabeth Brown, Antje Hoering, Benjamin Diamond, Bachisio Ziccheddu, Marc S. Raab, Niels Weinhold, Ola Landgren, Faith E Davies, Alexander M. Lesokhin, Saad Z. Usmani, Francesco Maura, Gareth Morgan

Blood (2024) 144 (Supplement 1): 766.

https://doi.org/10.1182/blood-2024-203675

Published: 2024

Journal Articles

Phase 2 Study of Teclistamab-Based Induction Regimens in Patients with Transplant-Eligible (TE) Newly Diagnosed Multiple Myeloma (NDMM): Results from the GMMG-HD10/DSMM-XX (MajesTEC-5) Trial

Blood (2024) 144 (Supplement 1): 493.

https://doi.org/10.1182/blood-2024-206003

Published: 2024

Journal Articles

Impact of Clonal Heterogeneity in Newly Diagnosed, Transplant-Eligible Multiple Myeloma - Subgroup Analysis of the GMMG HD6 Phase III Trial

Blood (2024) 144 (Supplement 1): 84.

https://doi.org/10.1182/blood-2024-201972

Published: 2024

Journal Articles

MRD By Flow Cytometry and FDG-PET/CT for the Post-Induction Response Assessment in Patients with Multiple Myeloma Treated in the Phase 3 GMMG HD7 Study

Marina Hajiyianni, Christos Sachpekidis, Annette Kopp-Schneider, Elias Karl Mai, Sandra Sauer, Ekaterina Menis, Michael Hundemer, Niels Weinhold, Jens Hillengass, Marc-Steffen Raab, Antonia Dimitrakopoulou-Strauss, Hartmut Goldschmidt

Blood (2024) 144 (Supplement 1): 4701.

https://doi.org/10.1182/blood-2024-210171

Published: 2024

Journal Articles

Genomic Complexity Correlates with the Degree of Marrow Independence of Malignant Plasma Cells in the Context of Extramedullary Disease

Blood (2024) 144 (Supplement 1): 248.

https://doi.org/10.1182/blood-2024-204341

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Feasibility and efficacy of daratumumab-vcd in transplant-ineligible elderly patients with newly diagnosed multiple myeloma: First results from the multicenter GMMG-dada study

Identify high-risk disease in multiple myeloma through single-cell transcriptomic detection of highly proliferative (PR) cells

Peripheral residual disease activity assessment by MALDI-TOF mass spectrometry in patients with newly-diagnosed multiple myeloma in the GMMG-HD7 study

Phylogenetic reconstruction reveals early divergence and late expansion of focal lesions in multiple myeloma

Circulating tumor cells (CTCs) for dynamic risk assessment of patients (Pts) with smoldering multiple myeloma (SMM)

T cell fitness and tumor specificity predict immunotherapy response in multiple myeloma

Reprogrammed regulatory T cells as cytotoxic effectors drive anti-tumor immunity under bispecific T cell engager therapy

Absence of circulating tumor cells (CTCs) defines a subtype of multiple myeloma (MM) patients (Pts) with unique clinical and biological features

Applying computational modelling to a high-risk multiple myeloma data set to create novel risk stratification groupings

The evolution to hepta-refractory myeloma involves sequential loss of CD38, BCMA and GPRC5D

Unlocking myeloma's spatial world at the micrometer scale

Biallelic antigen escape is a mechanism of resistance to anti-CD38 antibodies in multiple myeloma

Mutationally Enriched Regions of the Non-Coding Genome Harbor Functionally Impactful Mutations That Dysregulate Key Genes Involved in Multiple Myeloma Pathogenesis

Replication Stress Induces Hyper-Apobec Mutagenesis in Multiple Myeloma

The CAR-Hematotox As a Risk Model to Predict Early Complications and Outcome after Bispecific T-Cell Engager Therapy in Relapsed/Refractory Multiple Myeloma

Whole Genome Sequencing Reveals Lower Apobec-Mutational Activity in Multiple Myeloma Patients with African Ancestry Compared with Those Having European Ancestry

Phase 2 Study of Teclistamab-Based Induction Regimens in Patients with Transplant-Eligible (TE) Newly Diagnosed Multiple Myeloma (NDMM): Results from the GMMG-HD10/DSMM-XX (MajesTEC-5) Trial

Impact of Clonal Heterogeneity in Newly Diagnosed, Transplant-Eligible Multiple Myeloma - Subgroup Analysis of the GMMG HD6 Phase III Trial

MRD By Flow Cytometry and FDG-PET/CT for the Post-Induction Response Assessment in Patients with Multiple Myeloma Treated in the Phase 3 GMMG HD7 Study

Genomic Complexity Correlates with the Degree of Marrow Independence of Malignant Plasma Cells in the Context of Extramedullary Disease

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only